Beaufort Securities view on Advanced Oncotherapy (AVO)
Beaufort Securities view on Advanced Oncotherapy (AVO). It always comes as a surprise when the market reacts violently to some news item whose impact was considered already to be priced-in. Yesterday’s announcement told shareholders nothing new. Back in November, AVO detailed the fact that Sinophi was no longer to proceed with the installation of LIGHT […]
Advanced Oncotherapy (AVO) – Industrialisation agreement with Thales
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has finalised the details of the contract for manufacturing the first LIGHT machine with Thales. This forms part of the partnership with Thales that was announced in February 2016. Thales has selected one of its factories located in France, […]
Advanced Oncotherapy (AVO) – Recent article and Speculative Buy rating from Beaufort Securities
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, yesterday made two important announcements. One being the realignment of roles and responsibilities of the Executive team, the other being a prospectively far reaching industrialisation agreement with Thales, the giant and highly prestigious French multinational technology design and manufacturing group. 1) The agreement […]
Advanced Oncotherapy (AVO) – Directorate Change
Advanced Oncotherapy plc (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that following the continued successful development of the Company’s first LIGHT system and the recent industrialisation agreement with Thales, the Board has decided to realign the roles and responsibilities of the Executive team to add additional focus to both operational […]
Advanced Oncotherapy (AVO) – Thales industrialisation agreement
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has entered into an industrialisation agreement with Thales, for its proprietary LIGHT system. This agreement with Thales provides Advanced Oncotherapy with the support needed to move from the first LIGHT system, currently being developed for use at the Company’s flagship […]